Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes. Issue 1 (December 2017)

• Record Type: Journal Article
• Authors: Yasmin, Sabina; Capone, Fabio; Laghezza, Antonio; Piaz, Fabrizio; Loiodice, Fulvio; Vijayan, Viswanathan; Devadasan, Velmurugan; Mondal, Susanta; Atlı, Özlem; Baysal, Merve; Pattnaik, Ashok; Jayaprakash, Venkatesan; Lavecchia, Antonio
• Is Part Of: Scientific reports. Volume 7:Issue 1(2017)
• Page Start: 1
• Page End: 17
• Publication Date: 2017-12
• Subjects: Natural history -- Research -- Periodicals; Biology -- Research -- Periodicals; Physical sciences -- Research -- Periodicals; Earth sciences -- Research -- Periodicals; Environmental sciences -- Research -- Periodicals; 502.85
• DOI: 10.1038/s41598-017-14776-0
• Languages: English
• ISSNs: 2045-2322

Abstract

Abstract Peroxisome proliferator-activated receptor γ (PPARγ) has received significant attention as a key regulator of glucose and lipid homeostasis. In this study, we synthesized and tested a library of novel 5-benzylidene-thiazolidin-2, 4-dione (BTZD) derivatives bearing a substituent on nitrogen of TZD nucleus (compounds1a -1k, 2i -10i, 3a, 6a, and8a -10a ). Three compounds (1a, 1i, and3a ) exhibited selectivity towards PPARγ and were found to be weak to moderate partial agonists. Surface Plasmon Resonance (SPR) results demonstrated binding affinity of1a, 1i and3a towards PPARγ. Furthermore, docking experiments revealed that BTZDs interact with PPARγ through a distinct binding mode, forming primarily hydrophobic contacts with the ligand-binding pocket (LBD) without direct H-bonding interactions to key residues in H12 that are characteristic of full agonists. In addition, 1a, 1i and3a significantly improved hyperglycemia and hyperlipidaemia in streptozotocin-nicotinamide (STZ-NA)-induced diabetic rats at a dose of 36 mg/kg/day administered orally for 15 days. Histopathological investigations revealed that microscopic architecture of pancreatic and hepatic cells improved in BTZDs-treated diabetic rats. These findings suggested that1a, 1i and3a are very promising pharmacological agents by selectively targeting PPARγ for further development in the clinical treatment of type 2 diabetes mellitus.